ADMA Biologics announces $125M accelerated share repurchase with JPmorgan
Seeking Alpha News (Mon, 2-Mar 7:46 AM ET)
ADMA Biologics Launches Major 2026 Capital Return Plan
TipRanks (Mon, 2-Mar 7:45 AM ET)
Market Chameleon (Mon, 2-Mar 2:35 AM ET)
Globe Newswire (Mon, 2-Mar 7:00 AM ET)
Globe Newswire (Wed, 25-Feb 4:06 PM ET)
ADMA Biologics Sets Date to Unveil 2025 Financials—What Should Investors Watch for on February 25?
Market Chameleon (Wed, 18-Feb 4:43 AM ET)
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Globe Newswire (Wed, 18-Feb 7:00 AM ET)
Globe Newswire (Mon, 12-Jan 8:00 AM ET)
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
Globe Newswire (Mon, 5-Jan 7:00 AM ET)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Adma Biologics trades on the NASDAQ stock market under the symbol ADMA.
As of March 6, 2026, ADMA stock price declined to $15.39 with 2,863,175 million shares trading.
ADMA has a beta of 0.43, meaning it tends to be less sensitive to market movements. ADMA has a correlation of 0.03 to the broad based SPY ETF.
ADMA has a market cap of $3.66 billion. This is considered a Mid Cap stock.
Last quarter Adma Biologics reported $139 million in Revenue and $.22 earnings per share. This fell short of revenue expectation by $-637,000 and exceeded earnings estimates by $.02.
In the last 3 years, ADMA traded as high as $25.67 and as low as $2.95.
The top ETF exchange traded funds that ADMA belongs to (by Net Assets): IJR, VTI, IWM, XBI, VXF.
ADMA has underperformed the market in the last year with a price return of -13.0% while the SPY ETF gained +16.6%. ADMA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.5% and -5.7%, respectively, while the SPY returned -1.7% and -1.8%, respectively.
ADMA support price is $15.19 and resistance is $16.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADMA shares will trade within this expected range on the day.